Seelos_full logo and icon color.jpg
Seelos Therapeutics to Host Key Opinion Leader Call to Discuss Phase I Data and Upcoming Trial Design for SLS-002
June 15, 2020 08:01 ET | Seelos Therapeutics, Inc.
NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders...
Seelos_full logo and icon color.jpg
Seelos Therapeutics to Host Key Opinion Leader Call to Discuss the Unmet Medical Needs in Suicide and Depression
May 19, 2020 09:01 ET | Seelos Therapeutics, Inc.
NEW YORK, May 19, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
May 12, 2020 08:01 ET | Seelos Therapeutics, Inc.
NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)
March 24, 2020 08:01 ET | Seelos Therapeutics, Inc.
NEW YORK, March 24, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces Closing of Public Offering of Common Stock
March 16, 2020 16:30 ET | Seelos Therapeutics, Inc.
NEW YORK, March 16, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)
February 26, 2020 08:01 ET | Seelos Therapeutics, Inc.
NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces Pricing of $5 Million Public Offering of Common Stock
February 10, 2020 20:00 ET | Seelos Therapeutics, Inc.
NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces Interim Data from Phase I Study of Intranasal Racemic Ketamine (SLS-002)
January 10, 2020 07:31 ET | Seelos Therapeutics, Inc.
NEW YORK, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Schedules Type C Meeting with FDA to Discuss Intranasal Racemic Ketamine Program (SLS-002)
January 06, 2020 08:02 ET | Seelos Therapeutics, Inc.
NEW YORK, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces Dosing of Phase I PK/PD Study of Intranasal Racemic Ketamine (SLS-002)
November 27, 2019 11:00 ET | Seelos Therapeutics, Inc.
NEW YORK, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...